260 related articles for article (PubMed ID: 17851224)
1. AL amyloidosis with renal involvement.
Rysavá R
Kidney Blood Press Res; 2007; 30(6):359-64. PubMed ID: 17851224
[TBL] [Abstract][Full Text] [Related]
2. [Advances in diagnosis and treatment of AL amyloidosis].
Zelichowski G; Lubas A; Wańkowicz Z
Pol Merkur Lekarski; 2008 Apr; 24(142):340-5. PubMed ID: 18634370
[TBL] [Abstract][Full Text] [Related]
3. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support.
Sezer O; Schmid P; Shweigert M; Heider U; Eucker J; Harder H; Sinha P; Radtke H; Possinger K
Bone Marrow Transplant; 1999 May; 23(9):967-9. PubMed ID: 10338056
[TBL] [Abstract][Full Text] [Related]
4. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis.
Mignot A; Bridoux F; Thierry A; Varnous S; Pujo M; Delcourt A; Gombert JM; Goujon JM; Favreau F; Touchard G; Herpin D; Jaccard A
Haematologica; 2008 Mar; 93(3):e32-5. PubMed ID: 18310532
[TBL] [Abstract][Full Text] [Related]
5. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
Comenzo RL
Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
[TBL] [Abstract][Full Text] [Related]
6. [Primary amyloidosis associated to severe factor X deficiency].
Pérez Martínez J; Llamas F; López Montes A; Massó P; Poblet E; López Rubio E; Gallego E; Gómez Roldán C
Nefrologia; 2004; 24(5):493-8. PubMed ID: 15648909
[TBL] [Abstract][Full Text] [Related]
7. AL amyloidosis manifesting as systemic lymphadenopathy.
Matsuda M; Gono T; Shimojima Y; Yoshida T; Katoh N; Hoshii Y; Yamada T; Ikeda S
Amyloid; 2008 Jun; 15(2):117-24. PubMed ID: 18484338
[TBL] [Abstract][Full Text] [Related]
8. [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].
Thierry A; Bridoux F; Goodman H; Belmouaz S; Abou Ayache R; Desport E; Jaccard A; Touchard G
Nephrologie; 2004; 25(4):111-8. PubMed ID: 15291138
[TBL] [Abstract][Full Text] [Related]
9. Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma.
Samanez C; Domingo A; Cibeira MT; Miquel R; Soler M; Bladé J
Eur J Haematol; 2006 Jan; 76(1):83-5. PubMed ID: 16343276
[TBL] [Abstract][Full Text] [Related]
10. AL amyloidosis: advances in diagnostics and treatment.
Ryšavá R
Nephrol Dial Transplant; 2019 Sep; 34(9):1460-1466. PubMed ID: 30299492
[TBL] [Abstract][Full Text] [Related]
11. Primary amyloidosis of the kidney.
Shafique S; Wetmore J; Almehmi A
W V Med J; 2010; 106(1):22-4. PubMed ID: 20088306
[TBL] [Abstract][Full Text] [Related]
12. Neurologic complications of primary systemic amyloidosis.
Kelly JJ
Rev Neurol Dis; 2006; 3(4):173-81. PubMed ID: 17224900
[TBL] [Abstract][Full Text] [Related]
13. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation.
Gono T; Matsuda M; Dohi N; Hoshi K; Tada T; Sakashita K; Koike K; Aizawa M; Ikeda S
Intern Med; 2003 Jan; 42(1):72-7. PubMed ID: 12583623
[TBL] [Abstract][Full Text] [Related]
14. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
Bergesio F; Ciciani AM; Manganaro M; Palladini G; Santostefano M; Brugnano R; Di Palma AM; Gallo M; Rosati A; Tosi PL; Salvadori M;
Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
[TBL] [Abstract][Full Text] [Related]
15. Primary amyloidosis (AL) presenting with nephrotic syndrome: a case report and discussion.
Musolin L; Reyna R; DeBord J
W V Med J; 2003; 99(1):28-30. PubMed ID: 12762214
[TBL] [Abstract][Full Text] [Related]
16. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
[TBL] [Abstract][Full Text] [Related]
17. Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan.
Kawai Y; Kinoshita K; Arai H; Kuwata A; Fukuoka Y; Yamaoka M; Imamura S; Tsutani H; Ueda T
Eur J Haematol; 2004 Jun; 72(6):448-50. PubMed ID: 15128426
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
Breems DA; Sonneveld P; de Man RA; Leebeek FW
Eur J Haematol; 2004 Mar; 72(3):181-5. PubMed ID: 14962236
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management.
Gertz MA
Am J Hematol; 2011 Feb; 86(2):180-6. PubMed ID: 21264900
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment of AL amyloidosis.
Sezer O; Eucker J; Jakob C; Possinger K
Clin Nephrol; 2000 Jun; 53(6):417-23. PubMed ID: 10879660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
